COX-2 expression correlates with survival in patients with osteosarcoma lung metastases

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 7, 2008, Pages 507-512

  Rodriguez, Nidra I ^a,e   Hoots, William Keith ^a   Koshkina, Nadezhda V ^a   Morales Arias, Jaime A ^a   Arndt, Carola A ^b   Inwards, Carrie Y ^c   Hawkins, Douglas S ^d   Munsell, Mark F ^e   Kleinerman, Eugenie S ^a  

^a Children's Cancer Hospital   (United States)

^b Division of Pediatric Hematology/Oncology   (United States)

^c MAYO CLINIC   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

COX 2; Lung metastases; Osteosarcoma

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; ANTINEOPLASTIC AGENT; PTGS2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CHILD; CHILDHOOD CANCER; CLAVICLE; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FEMUR; FIBULA; HUMAN; HUMAN TISSUE; HUMERUS; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; KRUSKAL WALLIS TEST; LUNG METASTASIS; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NOTE; OSTEOSARCOMA; PELVIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; RETROSPECTIVE STUDY; SCHOOL CHILD; TIBIA; ADJUVANT THERAPY; ARTICLE; BONE TUMOR; CLINICAL TRIAL; ENZYMOLOGY; FOLLOW UP; LUNG RESECTION; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SALVAGE THERAPY; SURVIVAL; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PNEUMONECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 54449099511     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31816e238c     Document Type: Note

References (27)

1. Ries LAG, Smith MA, Gurney JG, et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub No. 99-4649 (chapters VIII and IX, p. 99-123). Bethesda, MD, 1999.
2. Putnam JB Jr, Roth JA, Wesley MN, et al. Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg. 1983; 36:516-523.
3. Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003;97:3068-3075.
4. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 2003;17:1986-1995.
5. Gasparini G, Longo R, Sarmiento R, et al. Inhibitors of cyclooxygenase-2: a new class of anticancer agents? Lancet. 2003; 4:605-615.
6. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;6:433-442.
7. Chun K, Surh Y. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharm. 2004;68:1089-1100.
8. Goodwin JS, Ceuppens JL. Regulation of immune response by prostaglandins. J Clin Immunol. 1983;3:295-315.
9. Eibl G, Takata Y, Boros LG, et al. Growth stimulation of COX-2 negative pancreatic cancer by a selective Cox-2 inhibitor. Cancer Res. 2005;65:982-990.
10. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
11. Chu J, Lloyd FL, Trifan OC, et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther.2003;2:1-7.
12. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest.1999;79:1469- 1477.
13. Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004;10:8465-8471.
14. Laga AC, Zander DS, Cagle PT. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer. Arch Pathol Lab Med. 2005;129:1113-1117.
15. Juuti A, Louhimo J, Nordling S, et al. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol.2006;59:382-386.
16. Seo SS, Song YS, Kang DH, et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol.2004;92:927-935.
17. Dickens DS, Kozielski R, Khan J, et al. Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol. 2002;5:356-364.
18. Dickens DS, Kozielski R, Leavey PJ, et al. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol. 2003;25:282-285.
19. Miser J, Arndt C, Smithson W, et al. Treatment of high-grade osteosarcoma (OGS) with ifosfamide (IFOF), Mesna (Mes), adriamycin (ADR), high-dose methotrexate (HDMTX), and cisplatin (CDDP), results of 2 pilot trials. Proc Am Soc Clin Oncol. 1994; 13:412A.
20. Arndt C, Miser J, Prichard D, et al. Treatment of high-grade osteosarcoma (OGS) with ifosfamide (IFOS), Mesna (MES), adriamycin (ADR), high-dose methotrexate (HDMTX), and cisplatin (CDDP). Med Pediatr Oncol. 1996;27:227A.
21. Meyers P, Schwartz C, Krailo M, et al. Osteosarcoma: a randomized prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
22. Endo M, Matsumura T, Yamaguchi U, et al. Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol. 2006;37:471-476.
23. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97:2978-2987.
24. Nakopoulou L, Mylona E, Papadaki I, et al. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology. 2005;72:241-249.
25. Bacci G, Longhi A, Bertoni F, et al. Primary high-grade osteosarcoma: comparison between preadolescent and older patients. J Pediatr Hematol Oncol. 2005;27:129-134.
26. Naruse T, Nishida Y, Hosono K, et al. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2 dependent and independent routes. Carcinogenesis. 2006;27:584-592.
27. Rahme E, Barkun AN, Toubouti Y, et al. The cyclooxygenase-2 selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology. 2003;25: 404-412.